Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Budesonide Oral Suspension (TAK-721) in Healthy Adults
NCT06268301Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2023
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of EPI-EE in eosinophilic esophagitis (EoE) (2 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Concentration at 24 hours, Area Under the Concentration-time Curve From Time 0 to Last Quantifiable Concentration at 24 hours and 1 more. Started Feb 2023; status: completed.
02
Drugs
EPI-EE
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT06268301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268301.